SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company developing cancer immunotherapies, led by galinpepimut-S (GPS), a WT1-targeted vaccine licensed from Memorial Sloan Kettering, and tambiciclib (SLS009), an oral CDK9 inhibitor. Shares traded at $16.04 shortly after Thursday's open, down 10.64% from the prior session's close of $17.95 — a decline of $1.91. The direction is unambiguously lower. The cause is verified and specific: SELLAS priced a $150 million public offering at $13.00 per share late Wednesday, a steep discount to the market price, triggering dilution and re-pricing pressure on a stock that had more than doubled two sessions earlier.
The company sold 11,538,462 new shares at $13.00 apiece, with gross proceeds expected to reach $150 million before fees; underwriters hold a 30-day option on another 1,730,769 shares that would lift the total to $172.5 million. J.P. Morgan and TD Cowen led the book, with Mizuho and others in the syndicate. The offering is expected to settle Friday, Nov. 20.
The $13.00 clearing level is the crux of Thursday's move. It sits 27.6% below Wednesday's $17.95 close and 32% below Tuesday's $19.15 close. For investors who bought during this week's rally, the deal effectively marked the stock at a level far under their entry, and the new shares add roughly 5.7% to the share count. The raise also comes despite $134.7 million of cash and equivalents on the balance sheet at Sept. 30, which makes it a pre-emptive launch-funding exercise rather than an emergency lifeline — a nuance that limits the selloff but does not remove the dilution overhang.
Thursday's decline extends a giveback that began Wednesday, when shares fell 6.3%. On Tuesday, SLS rocketed 156% after the Phase 3 REGAL trial of GPS met its primary endpoint in acute myeloid leukemia, showing median overall survival of 24.0 months versus 14.7 months for best available treatment — a 41% reduction in the risk of death, with a hazard ratio of 0.59 and a two-sided p-value of 0.035. The stock printed an intraday high of $24.89, then faded. A 156% one-day gain creates a deep pool of short-term holders with large gains, and the discounted financing gave them a concrete reason to realize them.
Volume has been extraordinary: roughly 50.3 million shares traded Tuesday and 20.6 million Wednesday, against a typical daily turnover of about 4–7 million shares — several times normal. Early Thursday turnover was far lighter than either session, consistent with a post-deal repricing rather than a fresh wave of institutional selling. This is a company-specific event, not a sector move; the decline is driven by dilution mechanics rather than a shift in biotech risk appetite, and no peer read-through is evident.
On technicals, $13.00 now functions as the reference floor created by the offering, and the stock is trading roughly 23% above it. The $24.89 spike high marks clear near-term resistance, while the pre-data $7.47 close is the deeper support zone.
The scale runs from 0 — no meaningful news and an ordinary move — to 100, meaning transformative news and an extreme, rare price move. This event scores 40 out of 100. The catalyst is genuinely material: a $150 million raise priced at a 27.6% discount is a major financing for a company of this size, and it mechanically resets the valuation reference. The price response, however, is ordinary by the stock's own standards. At 10.64%, Thursday's decline was only about 1.6 times the average absolute daily move of roughly 6.7%, and moves of equal or greater size occurred 10 times in the last 69 sessions. Strong news combined with a routine swing produces a middling score.
The immediate focus is Friday's expected closing of the offering and whether the stock can hold above the $13.00 deal price once the new shares begin trading. Beyond that, the calendar is dominated by the FDA meeting to align on a regulatory path for GPS, with a Biologics License Application targeted for the first half of 2027. Investors also await detailed REGAL results at an upcoming medical conference and Phase 2 tambiciclib data in relapsed or refractory AML at the ASH meeting in mid-December, alongside preliminary first-line AML data expected before year-end. Risks include regulatory timelines slipping, underwriter option exercise adding supply, and the possibility that further capital raises follow as launch preparation costs mount.
Tickeron's Trending AI Robots page highlights the automated strategies performing best in current market conditions. Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers are surfaced in this curated section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup rotates as conditions change. For readers tracking high-volatility names like this one, it offers a structured way to see which approaches are working right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
SLS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 53 similar instances where the stock broke above the upper band. In 47 of the 53 cases the stock fell afterwards. This puts the odds of success at 89%.
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for SLS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 60 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on SLS as a result. In 79 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for SLS just turned positive on November 17, 2026. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
SLS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.592). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of biopharmaceuticals
Industry Biotechnology